ClinicalTrials.Veeva

Menu

ThuLEP vs. HoLEP vs. Monopolar Enucleation in Management of BPH

I

I.M. Sechenov First Moscow State Medical University

Status

Completed

Conditions

Prostatic Hyperplasia, Benign
Prostate Adenoma
Lower Urinary Tract Symptoms

Treatments

Procedure: Monopolar enucleation of the prostate
Procedure: Ho:YAG laser enucleation of the prostate
Procedure: Thulium-fiber laser enucleation of the prostate

Study type

Interventional

Funder types

Other

Identifiers

NCT03230721
IMSechenovMMA

Details and patient eligibility

About

Today, endoscopic enucleation of the prostate (EEP) has been recognized a method of choice for treatment of benign prostatic hyperplasia (BPH) of any size, including large-sized glands (>80 cc). The goal of our study was to compare perioperative efficacy, functional outcomes and safety of different techniques of endoscopic enucleation of the prostate (monopolar enucleation, holmium laser enucleation, thulium laser enucleation) in a single center.

Full description

HoLEP and ThuLEP or EEP have been approved by the current guidelines of the European Association of Urology for use in men with substantially enlarged prostates (>80 ml) as first-line therapy [1]. This type of operation can be performed by means of several sources of energy.

To our knowledge, there were no studies comparing efficacy and complications of these three treatment modalities.

In this study the investigators have evaluated efficacy of Thulium-fiber laser enucleation (120 W thulium fiber laser Urolase, IPG IRE-POLUS, Russia with wavelength of 1940 nm) and monopolar enuclation in comparision with HoLEP (VersaPulse Powersuite 100, Lumenis, USA/Israel) in reduction of LUTS secondary to BPH in a prospective randomized trial.

All peri-operative parameters, urinary flow parameters, prostate size changes, erectile function and complications associated with the procedures were compared.

Enrollment

450 patients

Sex

Male

Ages

50 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • IPSS>20;
  • maximum urinary flow rate< 10ml\s (Qmax);
  • ineffective alfa-blockers therapy.

Exclusion criteria

  • histologically verified prostate cancer;
  • history of prostatic surgery;
  • urethral strictures;
  • bladder stones;
  • chronic urinary retention and cystostomy.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

450 participants in 3 patient groups

ThuLEP group
Active Comparator group
Description:
Patients who underwent thulium-fiber laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
Treatment:
Procedure: Thulium-fiber laser enucleation of the prostate
Monopolar enucleation group
Active Comparator group
Description:
Patients who underwent monopolar enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
Treatment:
Procedure: Monopolar enucleation of the prostate
HoLEP group
Active Comparator group
Description:
Patients who underwent Ho:YAG laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
Treatment:
Procedure: Ho:YAG laser enucleation of the prostate

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems